Clodronate in myelofibrosis: a case report

Am J Med Sci. 2002 Feb;323(2):115-6. doi: 10.1097/00000441-200202000-00012.

Abstract

A 59-year-old man had well-documented agnogenic myeloid metaplasia (AMM) with pancytopenia. Frequent blood transfusions were required over a 10-month period. Androgen therapy was not beneficial and treatment with interferon resulted in severe thrombocytopenia with no decrease in transfusion requirements. Treatment with clodronate at a daily oral dose of 30 mg/kg resulted in a marked decrease in bone marrow fibrosis, and gradual normalization of blood counts over an 8-month period. He has been transfusion independent for the last 33 months. We support the findings of a previous case report that oral bisphosphonate therapy may be of value in patients with AMM.

Publication types

  • Case Reports

MeSH terms

  • Antimetabolites / therapeutic use
  • Blood Transfusion
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / metabolism
  • Clodronic Acid / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / physiopathology

Substances

  • Antimetabolites
  • Clodronic Acid